Related Experiment Videos
Opioid peptides and primary biliary cirrhosis
1Department of Medicine, St James's University Hospital, Leeds.
BMJ (Clinical Research Ed.)
|December 10, 1988
Summary
Opioid peptides are elevated in liver disease. Blocking these with nalmefene improved symptoms like itching and fatigue in cirrhosis patients, suggesting a role for opioid signaling in liver disease manifestations.
Area of Science:
- Hepatology
- Neuroendocrinology
- Pharmacology
Background:
- Elevated plasma concentrations of endogenous opioid peptides, methionine enkephalin and leucine enkephalin, are observed in patients with liver disease.
- The precise contribution of these opioid peptides to the clinical symptoms of hepatic disease remains unclear.
Purpose of the Study:
- To investigate the role of opioid peptides in the clinical manifestations of liver disease.
- To assess the effects of blocking opioid receptors using nalmefene, a specific opioid antagonist, in patients with cirrhosis.
Main Methods:
- Nalmefene was administered to 11 patients diagnosed with cirrhosis.
- Observed and recorded patient responses, including opioid withdrawal reactions and changes in clinical symptoms and laboratory values.
Main Results:
- All 11 patients experienced a severe opioid withdrawal reaction upon initiating nalmefene.
- In nine patients with primary biliary cirrhosis, pruritus was significantly alleviated.
- Fatigue appeared to improve, and plasma bilirubin levels showed a modest decrease in most patients.
Conclusions:
- Blocking opioid receptors with nalmefene impacts certain metabolic abnormalities associated with liver disease.
- Opioid signaling may play a significant role in the pathophysiology of clinical symptoms in liver disease.
- Further research is warranted to elucidate the therapeutic potential of opioid antagonists in managing liver disease complications.